Should I buy Arbutus Biopharma Corp (ABUS)? · P/E 5.4, rev $180.1M
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
This page is a buy-decision checklist for Arbutus Biopharma Corp (ABUS), not a recommendation. Use the cached numbers below to judge valuation, quality, and risk against your own horizon.
Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
On valuation: ABUS currently screens at market cap $883.0M and trailing P/E 5.4. Compare that P/E and cap to the company's own history and to sector peers — a single ratio is not a buy or sell signal.
Read the latest ABUS 10-K/10-Q on the SEC page before you size a position. Filings beat a headline.
Not investment advice. If ABUS fits your process, the live tape and full model are on the ABUS stock and quote pages.
Not investment advice.